- Home
- TRVI vs PHAT Comparison
TRVI vs PHAT Comparison
Compare TRVI & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVI
- PHAT
- Stock Information
- Founded
- TRVI 2011
- PHAT 2018
- Country
- TRVI United States
- PHAT United States
- Employees
- TRVI N/A
- PHAT N/A
- Industry
- TRVI Biotechnology: Pharmaceutical Preparations
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- TRVI Health Care
- PHAT Health Care
- Exchange
- TRVI Nasdaq
- PHAT Nasdaq
- Market Cap
- TRVI 725.7M
- PHAT 820.8M
- IPO Year
- TRVI 2019
- PHAT 2019
- Fundamental
- Price
- TRVI $8.07
- PHAT $11.48
- Analyst Decision
- TRVI Strong Buy
- PHAT Strong Buy
- Analyst Count
- TRVI 9
- PHAT 5
- Target Price
- TRVI $20.72
- PHAT $16.40
- AVG Volume (30 Days)
- TRVI 2.9M
- PHAT 1.0M
- Earning Date
- TRVI 11-05-2025
- PHAT 11-06-2025
- Dividend Yield
- TRVI N/A
- PHAT N/A
- EPS Growth
- TRVI N/A
- PHAT N/A
- EPS
- TRVI N/A
- PHAT N/A
- Revenue
- TRVI N/A
- PHAT $114,039,000.00
- Revenue This Year
- TRVI N/A
- PHAT $207.52
- Revenue Next Year
- TRVI N/A
- PHAT $96.46
- P/E Ratio
- TRVI N/A
- PHAT N/A
- Revenue Growth
- TRVI N/A
- PHAT 1049.82
- 52 Week Low
- TRVI $2.36
- PHAT $2.21
- 52 Week High
- TRVI $9.92
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- TRVI 53.13
- PHAT 51.80
- Support Level
- TRVI $6.93
- PHAT $11.89
- Resistance Level
- TRVI $9.92
- PHAT $13.00
- Average True Range (ATR)
- TRVI 0.76
- PHAT 0.73
- MACD
- TRVI 0.11
- PHAT -0.15
- Stochastic Oscillator
- TRVI 37.96
- PHAT 13.14
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.